Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

(2021) Thomas A. Wadden et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

(2021) Melanie Davies et al.   LANCET

Once-Weekly Semaglutide in Adults with Overweight or Obesity

(2021) John P.H. Wilding et al.   NEW ENGLAND JOURNAL OF MEDICINE

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

(2020) Robert F. Kushner et al.   Obesity

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

(2020) Martin Friedrichsen et al.   DIABETES OBESITY & METABOLISM

Gaps to bridge: Misalignment between perception, reality and actions in obesity

(2019) Ian D. Caterson et al.   DIABETES OBESITY & METABOLISM

MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

(2019) Michael A Nauck et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2018) Fang-Hong Shi et al.   Frontiers in Pharmacology

Progress and challenges in anti-obesity pharmacotherapy

(2018) Daniel H Bessesen et al.   Lancet Diabetes & Endocrinology

Amylin – Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity

(2018) Christina Neuner Boyle et al.   Molecular Metabolism

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

(2018) Patrick M O'Neil et al.   LANCET

Combination therapy for obesity

(2017) John PH Wilding   JOURNAL OF PSYCHOPHARMACOLOGY

Health Effects of Overweight and Obesity in 195 Countries over 25 Years

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY

(2016) W. Timothy Garvey et al.   Endocrine Practice

Management of obesity

(2016) George A Bray et al.   LANCET

Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From aDiabetes CareEditors’ Expert Forum

(2015) William T. Cefalu et al.   DIABETES CARE

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

(2011) R. R. Wing et al.   DIABETES CARE

The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis

(2009) Daphne P Guh et al.   BMC PUBLIC HEALTH